ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6

Completed

Conditions: Hepatitis C

First Posted Date: 2017-10-06

Last Posted Date: 2021-05-19

Lead Sponsor: AbbVie

Target Recruit Count: 2118

Registration Number: NCT03303599

Locations: 🇮🇹
Azienda Ospedaliero - Universi /ID# 168130, Pisa, Italy
🇵🇱
NZOZ Przychodnia Specjalistycz /ID# 208334, Zychlin, Lodzkie, Poland
🇵🇱
Szpital Wojewodzki w Opolu /ID# 208444, Opole, Opolskie, Poland

and more 153 locations

Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Phase 3

Completed

Conditions: Uterine Fibroids
Heavy Menstrual Bleeding

Interventions: Drug: E2/NETA
Other: Elagolix Placebo
Drug: Elagolix
Other: E2/NETA Placebo

First Posted Date: 2017-09-05

Last Posted Date: 2024-07-19

Lead Sponsor: AbbVie

Target Recruit Count: 478

Registration Number: NCT03271489

Locations: 🇺🇸
Exordia Medical Research, Inc /ID# 160853, Fall River, Massachusetts, United States
🇺🇸
Health care Affiliates Medical Group /ID# 163324, Santa Ana, California, United States
🇺🇸
Duplicate_Northwell Health System - Manhasset /ID# 201058, Manhasset, New York, United States

and more 154 locations

A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis (axSpA)

Terminated

Conditions: Axial Spondyloarthritis

Interventions: Behavioral: Active Supervised Training (AST)
Behavioral: Standard of Care (SOC) Physiotherapy

First Posted Date: 2017-08-23

Last Posted Date: 2019-10-02

Lead Sponsor: AbbVie

Target Recruit Count: 17

Registration Number: NCT03258814

Locations: 🇩🇪
Rheumahaus Studien GbR, Potsdam, DE /ID# 164494, Potsdam, Brandenburg, Germany
🇩🇪
MVZ Wittenbergplatz PP Orthos /ID# 204802, Berlin, Germany
🇩🇪
Rheumapraxis /ID# 164461, Halle, Germany

and more 3 locations

A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Fumaderm
Drug: risankizumab

First Posted Date: 2017-08-21

Last Posted Date: 2019-09-13

Lead Sponsor: AbbVie

Target Recruit Count: 120

Registration Number: NCT03255382

Locations: 🇩🇪
Universitaetsklinik Heidelberg /ID# 161014, Heidelberg, Baden-Wuerttemberg, Germany
🇩🇪
Universitatsklinikum Frankfurt /ID# 161036, Frankfurt, Hessen, Germany
🇩🇪
Johannes Wesling Klin Minden /ID# 161015, Minden, Nordrhein-Westfalen, Germany

and more 20 locations

A Study of SC-007 in Subjects With Advanced Cancer

Phase 1

Terminated

Conditions: Colorectal Cancer (CRC)
Gastric Cancer

Interventions: Drug: SC-007

First Posted Date: 2017-08-17

Last Posted Date: 2018-04-27

Lead Sponsor: AbbVie

Target Recruit Count: 7

Registration Number: NCT03253185

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Washington University-School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States

and more 4 locations

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Phase 1

Completed

Conditions: Malignancies
Acute Lymphoblastic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Non-Hodgkin's Lymphoma
Neuroblastoma

Interventions: Drug: chemotherapy
Drug: venetoclax

First Posted Date: 2017-08-02

Last Posted Date: 2023-05-22

Lead Sponsor: AbbVie

Target Recruit Count: 143

Registration Number: NCT03236857

Locations: 🇫🇷
AP-HM - Hopital de la Timone /ID# 161465, Marseille CEDEX 05, Bouches-du-Rhone, France
🇺🇸
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 163444, New York, New York, United States
🇫🇷
Robert Debre Hopital, FR /ID# 161464, Paris, France

and more 28 locations

A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China

Completed

Conditions: Psoriasis

First Posted Date: 2017-08-02

Last Posted Date: 2021-10-14

Lead Sponsor: AbbVie

Target Recruit Count: 181

Registration Number: NCT03236870

Locations: 🇨🇳
Traditional Chinese Medical Hospital of xinjiang uygur autonomous region /ID# 209183, Wulumuqi, Xinjiang, China
🇨🇳
The 7th People's Hospital of Shenyang /ID# 169829, Shenyang, China
🇨🇳
The Second Affiliated Hospital /ID# 169842, Hangzhou, Zhejiang, China

and more 12 locations

Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection

Phase 3

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Drug: Glecaprevir/Pibrentasvir

First Posted Date: 2017-08-01

Last Posted Date: 2019-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 160

Registration Number: NCT03235349

Locations: 🇨🇳
Guangdong General Hospital /ID# 156827, Guangzhou, Guangdong, China
🇨🇳
The First Hosp of Jilin Univ /ID# 156825, Changchun, Jilin, China
🇨🇳
West China Hospital /ID# 156835, Chengdu, Sichuan, China

and more 31 locations

A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

Phase 1

Completed

Conditions: Advanced Solid Tumors Cancer

Interventions: Drug: ABBV-321

First Posted Date: 2017-07-31

Last Posted Date: 2021-05-06

Lead Sponsor: AbbVie

Target Recruit Count: 62

Registration Number: NCT03234712

Locations: 🇺🇸
Highlands Oncology Group /ID# 166132, Springdale, Arkansas, United States
🇺🇸
University of California, Davis Comprehensive Cancer Center /ID# 215012, Sacramento, California, United States
🇺🇸
Lifespan Cancer Institute at Rhode Island Hospital /ID# 168600, Providence, Rhode Island, United States

and more 15 locations

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

Phase 2

Active, not recruiting

Conditions: Myelofibrosis (MF)

Interventions: Drug: Navitoclax
Drug: Ruxolitinib

First Posted Date: 2017-07-19

Last Posted Date: 2024-06-27

Lead Sponsor: AbbVie

Target Recruit Count: 191

Registration Number: NCT03222609

Locations: 🇺🇸
University of Southern California /ID# 164095, Los Angeles, California, United States
🇺🇸
Dana-Farber Cancer Institute /ID# 162675, Boston, Massachusetts, United States
🇨🇦
Princess Margaret Cancer Centre /ID# 214483, Toronto, Ontario, Canada

and more 88 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy